Brief: Chugai Pharmaceutical Co Ltd Files NDA For Risdiplam For Spinal Muscular Atrophy In Japan
15/10/2020 17:04
Oct 15 (Reuters) - Chugai Pharmaceutical Co Ltd 4519.T :
* CHUGAI PHARMACEUTICAL CO LTD - FILES A NEW DRUG
APPLICATION FOR
RISDIPLAM AS THE FIRST ORAL DRUG FOR SPINAL MUSCULAR ATROPHY IN
JAPAN
Source text for Eikon: urn:newsml:reuters.com:*:nNDL7QQKVd
Further company coverage: 4519.T
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Chugai Pharmaceutical
See all newsRegarding Discontinuation Of Development Of Gym329 (Emugrobart) For Obesity, Return Of License And Resumption Of Development For SMA
Table: Chugai Pharm 6-MTH group results (IFRS)
Japan's Nikkei roars past 62,000 on earnings, Middle East optimism; JGBs rally (updated)
Japan's Nikkei surges past 61,000 for first time on earnings, Mideast optimism
Japan's Nikkei closes above 60,000 for first time on earnings optimism (updated)